01-01-1970 12:00 AM | Source: ARETE Securities Ltd
Key Stock News: IIFL fintech , M3M India, Vedanta, Byju's, Glenmark Pharma, Dabur - ARETE Securities
News By Tags | #6763 #6442 #23 #305 #7063 #572 #5162

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel

https://t.me/InvestmentGuruIndiacom

Download Telegram App before Joining the Channel

IIFL fintech fund picks up 16% in Insurance Samadhan for $2 million

The IIFL Group's early-stage investment vehicle, IIFL Fintech Fund, has invested USD 2 million (around Rs 16.5 crore) in insurance technology startup Insurance Samadhan for a 16 per cent stake, valuing the platform at around USD 13 million (around Rs 107 crore). The startup also received another USD 1 million from other investors in the series-A round.

This is IIFL fintech fund's 10th investment and first in the insuretech space, the company said, adding it has already invested 50 per cent of the Rs 210 crore corpus of the fund.

 

M3M India buys 350 acre land in Panipat for Rs 1,500 crore; to build township at Rs 2,700 crore cost 

M3M India buys 350-acre land in Haryana for ?1,500 cr; to develop township of ?2,700 cr. Last month, the company forayed into the Noida market by securing a 13-acre land parcel via e-auctions. The land was purchased from Ambience Group. This is another step for the company for becoming a panIndia player.

 

Vedanta announces incentives for purchase of EV’s by Employees

Globally diversified natural resources firm Vedanta Ltd on Tuesday said it has rolled out an EV policy for its employees, under which incentives ranging from 30 to 50 per cent will be provided on purchase of electric vehicles.

As part of its commitment towards net-zero carbon, the company has pledged 100 per cent of its light motor vehicles to be decarbonised by 2030.

 

Byju's buying phone numbers of children, threatening parents to buy courses, claims NCPCR

Edtech unicorn BYJU’s is in the news again for the wrong reasons. The National Commission for Protection of Child Rights (NCPCR) has summoned the CEO of the company, Byju Raveendran, for an in-person meeting on Friday, December 23.

The CEO is asked to appear in person before the commission over alleged malpractice of hard selling and mis-selling of courses.

 

Glenmark Pharma launches combination drug for diabetic patient

Glenmark Pharmaceuticals Ltd on Wednesday said it has launched triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India for diabetic patients.

This fixed-dose combination offers patients with Type 2 diabetes the convenience of once daily dosing to improve their glycemic control. It is priced at Rs 14.90 per day, thereby reducing the daily cost of therapy by 40 per cent, making it more affordable to the masses.

This fixed-dose combination offers patients with Type 2 diabetes the convenience of once daily dosing to improve their glycemic control. It is priced at Rs 14.90 per day, thereby reducing the daily cost of therapy by 40 per cent, making it more affordable to the masses.

 

Dabur promoters offload 1% stake through block deal

Home-grown FMCG major Dabur India on Tuesday said its promoters the Burman family have sold shares amounting to about 1 per cent stake in the company through the open market to raise funds for financing some ventures

"Burman family, who are part of the majority shareholders of Dabur India Ltd, have sold approximately 1 per cent shares through a block deal," said a regulatory filing by Dabur India.

 

To Read Complete Report & Disclaimer Click Here

 

Please refer disclaimer at http://www.aretesecurities.com/
SEBI Regn. No.: INM000012740

 

Above views are of the author and not of the website kindly read disclaimer